Ultimovacs ASA: Annual Report 2020

Oslo, 25 March 2021: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a pharmaceutical company developing novel immunotherapies against cancer, announces that the Board of Directors in Ultimovacs ASA has approved the Annual Report for 2020. Please find a PDF version of the report enclosed. The Annual Report is also available at the company’s website: www.ultimovacs.com


This information is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.


For further information, please see www.ultimovacs.com or contact:

Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA

Email: je@radforsk.no

Phone: +47 480 96 355


Carlos de Sousa, CEO

Email: carlos.desousa@ultimovacs.com

Phone: +47 908 92507


Hans Vassgård Eid, CFO

Email: hans.eid@ultimovacs.com

Phone: +47 482 48632